In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they ...

GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Funding will advance Strand’s pipeline and mission to bring targeted, next-generation mRNA therapies to patients ...

Intellia expects to present additional data from the ongoing Phase 1/2 study in the second half of 2025. The Company is on track to submit a Biologics License Application (BLA) in the second half of ...

The competitive landscape of the ARMD market in 2025 is dominated by a few key players and a leading product. Eylea, a therapy for age-related molecular degeneration, is projected to command a ...

Regeneron Pharmaceuticals, Inc. saw a significant boost in ownership by Raiffeisen Bank International AG. The bank now ...

The FDA reviews odronextamab's application for relapsed lymphoma, highlighting trial enrollment issues but confirming safety and efficacy.

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

The FDA issued another complete response letter for odronextamab for the treatment of relapsed/refractory follicular lymphoma.